Research & Development
Ridgeback granted priority review of FDA application for potential Ebola treatment
30 July 2020 -

Botechnology company Ridgeback Biotherapeutics LP said on Wednesday that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its investigational Ebola treatment, ansuvimab (mAb114), and granted priority review designation.

Ansuvimab is a monoclonal antibody isolated from a human survivor of the 1995 Ebola outbreak in Kikwit, Democratic Republic of the Congo.

According to Wendy Holman, CEO and co-founder of Ridgeback, the treatment has demonstrated "an impressive survival benefit" in Ebola patients.

The FDA previously granted Breakthrough Therapy Designation status to ansuvimab as a treatment for Ebola in September 2019.



Related Headlines